To evaluate the usefulness of a high-sensitivity assay kit for E
2, we measured the serum E
2 levels in children. The value in a girl with true central precocious puberty was also evaluated before the LH-RH analogue treatment. The study subjects were 36 boys, ranging in age from 1 yr and 9 mo to 17 yr and 6 mo and 46 girls, ranging in age from 1 yr to 15 yr and 6 mo. The minimal detection limit was 1.4 pg/ml. The serum E
2 level in the boys and that in girls were 10.8 ± 3.1 pg/ml (mean ± SEM) and 20.7 ± 10.7 pg/ml, respectively. The E
2 level was correlated closely with bone age and chronological age. Even when the range of serum E
2 was limited to an undetectable level (<10 pg/ml) by the conventional assay, the logarithmic value for the E
2 concentration was correlated with bone age in boys (r=0.734, p<0.05) and in girls (r=0.404, p<0.05). The E
2 level in girls with partial and true precocious puberty ranged from 2.6 to 8.7 pg/ml. In a patient, who was originally considered as premature thelarche and later turned out to be true central precocious puberty, the serum E
2 level was 3.7 pg/ml before therapy, suggesting that high sensitivity to estrogen was the cause of the condition. With LH-RH analogue treatment, the E
2 level declined to below the detection limit and the bone age did not change for 1 yr without loss of linear growth. These results suggest that the high-sensitivity kit is useful for monitoring the pathophysiology of E
2 in children.
View full abstract